CaaS Capital Management

Founded 2019

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 8
Average round size
info
The average size of a deal this fund participated in
$113M
Portfolio companies 10
Rounds per year 4.00
Lead investments 0
Exits 1
Key employees Soon
Stages of investment
Late Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Biopharma
  • Pharmaceutical
  • Health Care

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

T-knife

Biotechnology
$110M02 Aug 2021 Berlin, Berlin, Germany

Artios Pharma

Biopharma
Biotechnology
Medical Device
$150M27 Jul 2021 Cambridge, England, United Kingdom

Turnstone Biologics

Biotechnology
Innovation Management
Therapeutics
$80M14 Jul 2021 San Francisco, California, United States

Umoja Biopharma

Biopharma
Biotechnology
Developer Platform
Information Technology
$210M15 Jun 2021 Seattle, Washington, United States

Arcellx

Biopharma
Health Care
Pharmaceutical
$115M13 Apr 2021 Maryland, United States

Rapid Micro Biosystems

Biotechnology
Manufacturing
Pharmaceutical
$81M16 Mar 2021 Massachusetts, United States

Cyteir Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$80M11 Feb 2021 Cambridge, Massachusetts, United States
News
T-knife Therapeutics Closes $110M Series B Financing

– T-knife Therapeutics, Inc. from Berlin, Germany develops T-cell receptor (TCR) therapeutics for solid tumor patients.
– Company completed a $110m Series B financing.
– The round was led by Fidelity Management & Research Company, LLC., with participation from other new investors including LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners.
– The new investment will be used to expand the company’s scientific team, increase manufacturing capacity and advance its pipeline of TCR-T.

Turnstone Biologics Raises $80 Million Series D Financing

– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CaaS Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: